Oxaliplatin

Earn CME/CE in your profession:

Free Review Questions

Continuing Education Activity

Oxaliplatin is a medication used to manage and treat metastatic colorectal cancer. It is a member of the platinum-based chemotherapeutic class of drugs and is indicated in the adjunctive treatment of stage III colorectal cancer after resection of the primary tumor and for the treatment of metastatic colorectal cancer. It is FDA-approved in combination with infusional 5-fluorouracil and leucovorin. This activity reviews the indications, actions, and contraindications for oxaliplatin as a valuable agent in treating colorectal cancer and will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, relevant interaction) pertinent for members of the healthcare team in the treatment of patients with metastatic colorectal cancer and related conditions.

Objectives:

  • Identify the mechanism of action of oxaliplatin.
  • Describe the potential adverse effects of oxaliplatin.
  • Review the appropriate monitoring for patients receiving therapy with oxaliplatin.
  • Outline interprofessional team strategies for improving care coordination and communication to advance oxaliplatin and improve outcomes.

Indications

Oxaliplatin is an FDA-approved platinum-based antineoplastic medication.[1] It is indicated in the adjunctive treatment of stage III colorectal cancer after resection of the primary tumor and for the treatment of metastatic colorectal cancer.[1][2] It is FDA-approved in combination with infusional 5-fluorouracil and leucovorin in a regimen known as FOLFOX.[1]

In the pediatric population, oxaliplatin is used for treating refractory or relapsed solid tumors in combination with etoposide or ifosfamide or gemcitabine or irinotecan or fluorouracil, and leucovorin.[3][4][5][6][7] Oxaliplatin is also used to treat refractory or relapsed neuroblastoma in combination with doxorubicin.[8][9]

The following are the off-label indications for oxaliplatin:

  • Advanced biliary adenocarcinoma in combination with capecitabine (a regimen known as CAPOX) or gemcitabine.[10][11]
  • Fludarabine refractory chronic lymphocytic leukemia in combination with fludarabine, cytarabine, and rituximab.[12]
  • Esophageal and gastric cancers in combination with epirubicin or capecitabine or docetaxel, leucovorin, and fluorouracil.[13][14][15]
  • Refractory neuroendocrine tumors in combination with capecitabine.[16]
  • Refractory or relapsed non-Hodgkin lymphoma in combination with gemcitabine and rituximab.[17]
  • Advanced ovarian cancer.[18][
  • Advanced pancreatic cancer in combination with capecitabine or fluorouracil, leucovorin, and irinotecan.[19][20]
  • Refractory testicular cancer in combination with gemcitabine and paclitaxel.[21]

Mechanism of Action

Oxaliplatin is an alkylating agent and has non-cell cycle-specific cytotoxicity.[1] The platinum complex in the drug binds to DNA and forms cross-links.[22] The cross-links inhibit DNA replication, transcription, and arrest of the cell cycle, resulting in cell death.[22] It works synergistically with fluoropyrimidines such as 5-fluorouracil.[1] Oxaliplatin effectively treats fast-growing tumors like those in the gastrointestinal system, with a high cell turnover rate.[22]

The pharmacokinetics of unbound platinum in plasma following oxaliplatin administration were triphasic, demonstrating a short initial distribution phase followed by a prolonged terminal elimination phase. Oxaliplatin is subject to rapid and extensive nonenzymatic biotransformation and is not metabolized by the CYP450 enzyme system.[23] Oxaliplatin half-life varies significantly depending on the resource consulted and the method used to determine half-life.[24] It is excreted in the urine (approximately 50%) and the feces (2%).

As monotherapy, oxaliplatin only demonstrates modest antineoplastic activity against advanced colorectal cancer, but it is effective in combination therapy.[25]

Administration

Oxaliplatin administration is via intravenous infusion (IV) over two hours.[26] In cases of acute toxicity, the administration is extended to 6 hours.[26] The recommended infusion rate is 1mg/m^2/minute or 85 mg/m^2 dose over 85 minutes every two weeks.[26] Oxaliplatin is moderately emetogenic.[27] To prevent chemotherapy-induced nausea and vomiting (CINV), pretreatment with antiemetics is strongly recommended.[27]

Before administration, ensure proper needle and catheter placement to prevent extravasation and flush the infusion line with D5W.[28] It is common for patients to have vascular pain near the site of IV infusion; pretreatment with fast-acting oxycodone is a recommendation.[29] Monitor the IV site for irritation, redness, pain, and swelling.[29] In the event of extravasation, immediately discontinue treatment, remove the infusion line, aspirate the solution, do not flush, elevate the site and place a warm compress over the infusion site; a cold compress is contraindicated as it can cause acute neurological symptoms.[28]

Adult administration regimens are as follows: (consult facility protocols and manufacturer's package insert for dosing, pre-medications, and toxicity-based dose adjustments)

  • As an adjuvant in stage III colon cancer: 85 mg/m^2 IV for a single dose on day one of a 14-day cycle, used with 5-FU and leucovorin. Administer 12 cycles.
  • Advanced colorectal cancer: 85 mg/m^2 IV for a single dose on day one of a 14-day cycle, used with 5-FU and leucovorin.

There is no pediatric indication for oxaliplatin.

Dosing in patients with renal insufficiency (creatinine clearance less than 30): Start 65 mg/m^2 for one dose on day one of a 14-day cycle. Hepatic dosing is undefined.

Adverse Effects

The most common adverse drug effects reported with oxaliplatin monotherapy are:

  • Systemic: fever, fatigue, nausea, emesis, weakness[30][27]
  • Nervous system: peripheral sensory neuropathy, pain, headache, insomnia[31]
  • Gastrointestinal system: diarrhea, abdominal pain, constipation, anorexia, stomatitis[22]
  • Hepatic: elevated serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin[22]
  • Hematologic and oncologic: anemia, thrombocytopenia, leukopenia[22]
  • Musculoskeletal: back pain[32]
  • Respiratory system: dyspnea, cough[30]

Contraindications

Oxaliplatin is contraindicated in patients who have/are:

  • Platinum hypersensitivity anaphylaxis[30]
  • Posterior reversible encephalopathy syndrome[33]
  • Grade 3 or 4 peripheral sensory neuropathy[34]
  • Severe renal impairment[35]
  • Chronic lung disease[36]
  • Rhabdomyolysis[37]
  • Sepsis[38]
  • Pregnant or intending to get pregnant[39]
  • Breastfeeding[39]

Use in the first trimester should be avoided due to high teratogenicity and embryo or fetal death. Females of reproductive potential should have a pregnancy test prior to initiating therapy and must use appropriate contraception during treatment and for nine months following discontinuation of oxaliplatin. Male patients should continue contraception for six months following treatment cessation.[40] Patients should avoid breastfeeding during treatment and for three months following treatment termination. While there is no data available to assess infant harm in breastfeeding, excretion into breast milk is possible based on the drug's properties. There is no data on oxaliplatin's effect on milk production.

Monitoring

Patients on oxaliplatin therapy must periodically have blood and urine work up to assess complete blood count with differential, basic metabolic panel, liver function tests, renal function tests, and electrocardiogram (ECG) for QT prolongation.[22] It is essential to do a pregnancy test on women of reproductive age before initiating treatment.[22]

Oxaliplatin has a narrow therapeutic index, which most commonly affects the hematopoietic and nervous systems and has gastrointestinal side effects.[22] Periodic neurological exams are a recommendation to assess for acute or chronic oxaliplatin-induced peripheral neuropathy[22]

Drug interactions: Oxaliplatin requires close monitoring when administered with other drugs as it can enhance the adverse/toxic effects or diminish the therapeutic effects. The following drug interactions are important to consider:

  • Baricitinib
  • Disease-modifying anti-rheumatic drugs (DMARDs)
  • Chloramphenicol
  • Cladribine
  • Clozapine
  • Deferiprone
  • Denosumab
  • Dipyrone
  • Echinacea
  • Erdafitinib
  • Fingolimod
  • Fosphenytoin-phenytoin
  • Haloperidol
  • Leflunomide
  • Lenograstim
  • Lipegfilgrastim
  • Mesalamine
  • Natalizumab
  • Nivolumab
  • Ocrelizumab
  • Palifermin
  • Pidotimod
  • Pimecrolimus
  • Promazine
  • QT-prolonging agents
  • Roflumilast
  • Siponimod
  • Sipuleucel-T 
  • Tacrolimus
  • Tafenoquine
  • Taxane derivatives
  • Tertomotide
  • Tofacitinib
  • Topotecan
  • Upadacitinib
  • Vaccines

Toxicity

No known antidote exists for oxaliplatin overdose. Oxaliplatin has dose-dependent toxicity on the hematopoietic system. It causes myelosuppression, anemia, and thrombocytopenia.[22] In rare cases with repeated oxaliplatin treatment, hypersensitivity reactions, hemolytic anemia, and secondary immune thrombocytopenia can occur.[22] The therapy is discontinuation and symptomatic management.[22]

Oxaliplatin has dose-limiting toxicity on the nervous system.[22] It can cause acute or chronic peripheral neuropathy.[22] Acute oxaliplatin-induced peripheral neuropathy presents with paresthesia, dysesthesias, or allodynia, usually around the mouth and throat during or after the treatment.[22] Exposure to cold can also trigger these symptoms.[22] The symptoms resolve within a few hours to days following discontinuation.[34] Additional precautions are possible by prolonging the infusion time from two hours to six hours.[34]

Repeated oxaliplatin treatment can result in chronic peripheral neuropathy.[22] It manifests in the distal extremities with paresthesia, hypoesthesia, dysesthesia, and decreased proprioception.[22] It is seen in 10% of patients who receive a cumulative dose of 780 mg/m^2 (9 doses of 85mg/m^2) and 50% of patients who receive a cumulative dose of 1170 mg/m^2 (13 doses).[34] One study has shown a decreased incidence of neurotoxicity in patients receiving supplemental infusions of calcium and magnesium on the day of oxaliplatin administration.[34] There is preliminary and conflicting data on the use of oral n-acetylcysteine, xaliproden, gabapentin, carbamazepine, amifostine, and glutathione in the prevention or amelioration of oxaliplatin-induced neuropathy.[34]

Enhancing Healthcare Team Outcomes

Interprofessional treatment teams consisting of clinicians (MDs, DOs, NPs, and PAs), oncology specialists, nurses, laboratory technologists, pharmacists, and clinicians in different specialties need to be knowledgeable regarding the use and potential adverse events of oxaliplatin. This interprofessional team approach ensures proper administration, management, monitoring, and limitation of the adverse effects. When a patient is on a chemotherapeutic regimen, it is strongly advised to utilize a board-certified oncology specialty pharmacist who can examine the treatment regimen (including pre and post medication), communicate possible drug interactions, and the recommended therapeutic dosage to the clinician.

The assigned nursing staff must monitor the IV site, be cognizant of the adverse effects of the drug, and relay them to the clinician and/or pharmacist. As with pharmacy, having oncology-certified nurses involved in the pre-and post-administration care, in addition to performing administration, can optimize patient outcomes. These nurses will report to the ordering clinician any issues or concerns they see so remedial action (dose adjustments, additional medication, etc.) can be implemented.

Lastly, the clinician must have enough information to determine if the patient is a candidate to receive a drug like oxaliplatin depending on the patient's medical history; here again, consulting with an oncology pharmacist can prove invaluable.

The interpersonal healthcare team is responsible for the following:

  • Complete blood count, liver function tests, renal function tests, pregnancy test
  • Proper administration of the drug and monitoring of the IV site
  • Monitoring toxicity
  • Monitor the patient for signs and symptoms of CINV, peripheral sensory neuropathy, infection, GI disturbances
  • Consult with the pharmacist and toxicologist regarding dosing
  • Consult with the radiologist, pathologist, and surgeon regarding the spread of cancer

The prevention and management of oxaliplatin-induced neurotoxicity start with the patient limiting exposure to cold environments, ensuring proper protection, and staying away from cold food and beverages.[22] One study has shown a decrease in neurotoxicity in patients who received calcium and magnesium infusions before or after oxaliplatin administration.[41] [Level 2] In addition to changing the dosage, the interprofessional treatment team may consider supplementing oxaliplatin with calcium or magnesium in the event of peripheral sensory neuropathy.

WIth an interprofessional team approach to oxaliplatin therapy, patients stand to achieve the best possible outcomes with this drug while minimizing potential adverse effects. [Level 5]

Details

Author

Bhavana Devanabanda

Editor:

Anup Kasi

Updated:

5/16/2023 11:11:22 PM

Feedback:

Send Us Your Comments

References

[1]

Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. The New England journal of medicine. 2005 Feb 3:352(5):476-87     [PubMed PMID: 15689586]

[2]

Noepel-Duennebacke S, Arnold D, Hertel J, Tannapfel A, Hinke A, Hegewisch-Becker S, Reinacher-Schick A. Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial. Clinical colorectal cancer. 2018 Dec:17(4):e733-e739. doi: 10.1016/j.clcc.2018.07.007. Epub 2018 Jul 25     [PubMed PMID: 30145148]

[3]

Lam CG, Furman WL, Wang C, Spunt SL, Wu J, Ivy P, Santana VM, McGregor LM. Phase I clinical trial of ifosfamide, oxaliplatin, and etoposide (IOE) in pediatric patients with refractory solid tumors. Journal of pediatric hematology/oncology. 2015 Jan:37(1):e13-8. doi: 10.1097/MPH.0000000000000186. Epub     [PubMed PMID: 24942022]

Level 1 (high-level) evidence

[4]

McGregor LM,Spunt SL,Santana VM,Stewart CF,Ward DA,Watkins A,Laningham FH,Ivy P,Furman WL,Fouladi M, Phase 1 study of an oxaliplatin and etoposide regimen in pediatric patients with recurrent solid tumors. Cancer. 2009 Feb 1;     [PubMed PMID: 19117350]

[5]

Geoerger B, Chisholm J, Le Deley MC, Gentet JC, Zwaan CM, Dias N, Jaspan T, Mc Hugh K, Couanet D, Hain S, Devos A, Riccardi R, Cesare C, Boos J, Frappaz D, Leblond P, Aerts I, Vassal G, European Consortium Innovative Therapies for Children with Cancer (ITCC). Phase II study of gemcitabine combined with oxaliplatin in relapsed or refractory paediatric solid malignancies: An innovative therapy for children with Cancer European Consortium Study. European journal of cancer (Oxford, England : 1990). 2011 Jan:47(2):230-8. doi: 10.1016/j.ejca.2010.09.015. Epub 2010 Oct 11     [PubMed PMID: 20943374]

[6]

Macy ME, Duncan T, Whitlock J, Hunger SP, Boklan J, Narendren A, Herzog C, Arceci RJ, Bagatell R, Trippett T, Christians U, Rolla K, Ivy SP, Gore L, Pediatric Oncology Experimental Therapeutics Investigators' Consortium (POETIC). A multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors. Pediatric blood & cancer. 2013 Feb:60(2):230-6. doi: 10.1002/pbc.24278. Epub 2012 Sep 28     [PubMed PMID: 23024067]

[7]

Hartmann C, Weinel P, Schmid H, Grigull L, Sander A, Linderkamp C, Welte K, Reinhardt D. Oxaliplatin, irinotecan, and gemcitabine: a novel combination in the therapy of progressed, relapsed, or refractory tumors in children. Journal of pediatric hematology/oncology. 2011 Jul:33(5):344-9. doi: 10.1097/MPH.0b013e31820994ec. Epub     [PubMed PMID: 21572345]

[8]

Mascarenhas L, Malogolowkin M, Armenian SH, Sposto R, Venkatramani R. A phase I study of oxaliplatin and doxorubicin in pediatric patients with relapsed or refractory extracranial non-hematopoietic solid tumors. Pediatric blood & cancer. 2013 Jul:60(7):1103-7. doi: 10.1002/pbc.24471. Epub 2013 Jan 17     [PubMed PMID: 23335436]

[9]

Tran HC, Marachelian A, Venkatramani R, Jubran RF, Mascarenhas L. Oxaliplatin and Doxorubicin for relapsed or refractory high-risk neuroblastoma. Pediatric hematology and oncology. 2015 Feb:32(1):26-31. doi: 10.3109/08880018.2014.983624. Epub 2014 Dec 31     [PubMed PMID: 25551355]

[10]

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J, Tabah-Fisch I, de Gramont A, Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. The New England journal of medicine. 2004 Jun 3:350(23):2343-51     [PubMed PMID: 15175436]

[11]

Nehls O, Oettle H, Hartmann JT, Hofheinz RD, Hass HG, Horger MS, Koppenhöfer U, Hochhaus A, Stieler J, Trojan J, Gregor M, Klump B. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. British journal of cancer. 2008 Jan 29:98(2):309-15. doi: 10.1038/sj.bjc.6604178. Epub 2008 Jan 8     [PubMed PMID: 18182984]

[12]

Tsimberidou AM, Wierda WG, Plunkett W, Kurzrock R, O'Brien S, Wen S, Ferrajoli A, Ravandi-Kashani F, Garcia-Manero G, Estrov Z, Kipps TJ, Brown JR, Fiorentino A, Lerner S, Kantarjian HM, Keating MJ. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2008 Jan 10:26(2):196-203. doi: 10.1200/JCO.2007.11.8513. Epub     [PubMed PMID: 18182662]

[13]

Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR, Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom. Capecitabine and oxaliplatin for advanced esophagogastric cancer. The New England journal of medicine. 2008 Jan 3:358(1):36-46. doi: 10.1056/NEJMoa073149. Epub     [PubMed PMID: 18172173]

[14]

Al-Batran SE, Hartmann JT, Hofheinz R, Homann N, Rethwisch V, Probst S, Stoehlmacher J, Clemens MR, Mahlberg R, Fritz M, Seipelt G, Sievert M, Pauligk C, Atmaca A, Jäger E. Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Nov:19(11):1882-7. doi: 10.1093/annonc/mdn403. Epub 2008 Jul 31     [PubMed PMID: 18669868]

[15]

Conroy T, Yataghène Y, Etienne PL, Michel P, Senellart H, Raoul JL, Mineur L, Rives M, Mirabel X, Lamezec B, Rio E, Le Prisé E, Peiffert D, Adenis A. Phase II randomised trial of chemoradiotherapy with FOLFOX4 or cisplatin plus fluorouracil in oesophageal cancer. British journal of cancer. 2010 Oct 26:103(9):1349-55. doi: 10.1038/sj.bjc.6605943. Epub 2010 Oct 12     [PubMed PMID: 20940718]

Level 1 (high-level) evidence

[16]

Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer chemotherapy and pharmacology. 2007 Apr:59(5):637-42     [PubMed PMID: 16937105]

[17]

López A, Gutiérrez A, Palacios A, Blancas I, Navarrete M, Morey M, Perelló A, Alarcón J, Martínez J, Rodríguez J. GEMOX-R regimen is a highly effective salvage regimen in patients with refractory/relapsing diffuse large-cell lymphoma: a phase II study. European journal of haematology. 2008 Feb:80(2):127-32     [PubMed PMID: 18005385]

[18]

Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaïne MA, Tabah-Fisch I, Pouillart P. Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2002 Feb:13(2):258-66     [PubMed PMID: 11886003]

[19]

Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 2008 Oct 15:113(8):2046-52. doi: 10.1002/cncr.23810. Epub     [PubMed PMID: 18756532]

[20]

Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardière C, Bennouna J, Bachet JB, Khemissa-Akouz F, Péré-Vergé D, Delbaldo C, Assenat E, Chauffert B, Michel P, Montoto-Grillot C, Ducreux M, Groupe Tumeurs Digestives of Unicancer, PRODIGE Intergroup. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. The New England journal of medicine. 2011 May 12:364(19):1817-25. doi: 10.1056/NEJMoa1011923. Epub     [PubMed PMID: 21561347]

[21]

Bokemeyer C, Oechsle K, Honecker F, Mayer F, Hartmann JT, Waller CF, Böhlke I, Kollmannsberger C, German Testicular Cancer Study Group. Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group. Annals of oncology : official journal of the European Society for Medical Oncology. 2008 Mar:19(3):448-53     [PubMed PMID: 18006893]

[22]

Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Current oncology (Toronto, Ont.). 2011 Jan:18(1):18-25     [PubMed PMID: 21331278]

[23]

Graham MA, Lockwood GF, Greenslade D, Brienza S, Bayssas M, Gamelin E. Clinical pharmacokinetics of oxaliplatin: a critical review. Clinical cancer research : an official journal of the American Association for Cancer Research. 2000 Apr:6(4):1205-18     [PubMed PMID: 10778943]

[24]

Ehrsson H,Wallin I,Yachnin J, Pharmacokinetics of oxaliplatin in humans. Medical oncology (Northwood, London, England). 2002;     [PubMed PMID: 12512920]

[25]

Bécouarn Y, Ychou M, Ducreux M, Borel C, Bertheault-Cvitkovic F, Seitz JF, Nasca S, Nguyen TD, Paillot B, Raoul JL, Duffour J, Fandi A, Dupont-André G, Rougier P. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Aug:16(8):2739-44     [PubMed PMID: 9704726]

[26]

Cercek A, Park V, Yaeger R, Reidy-Lagunes D, Kemeny NE, Stadler ZK, Segal NH, Varghese A, Saltz LB. Faster FOLFOX: Oxaliplatin Can Be Safely Infused at a Rate of 1 mg/m2/min. Journal of oncology practice. 2016 May:12(5):e548-53. doi: 10.1200/JOP.2015.008417. Epub 2016 Apr 12     [PubMed PMID: 27072569]

[27]

Hatakeyama S, Suzuki N, Abe K, Konno N, Kaneko T, Toyoguchi T, Shiraishi T. [Effects of Serum Sodium Concentrations on Nausea and Vomiting after Moderately Emetogenic Chemotherapy]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan. 2018:138(8):1095-1101. doi: 10.1248/yakushi.18-00009. Epub     [PubMed PMID: 30068850]

[28]

de Lemos ML, Walisser S. Management of extravasation of oxaliplatin. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2005 Dec:11(4):159-62     [PubMed PMID: 16595069]

[29]

Suga Y, Ikeda N, Maeda M, Staub AY, Shimada T, Yonezawa M, Kitade H, Katsura H, Okada M, Ishizaki J, Sai Y, Matsushita R. Risk factors for oxaliplatin-induced vascular pain in patients with colorectal cancer and comparison of the efficacy of preventive methods. Journal of pharmaceutical health care and sciences. 2018:4():18. doi: 10.1186/s40780-018-0117-z. Epub 2018 Aug 7     [PubMed PMID: 30094053]

[30]

Khurana A, Mitsis D, Kowlgi GN, Holle LM, Clement JM. Atypical presentation of fever as hypersensitivity reaction to oxaliplatin. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2016 Apr:22(2):319-24. doi: 10.1177/1078155214558350. Epub 2014 Oct 30     [PubMed PMID: 25361599]

[31]

Saif MW,Reardon J, Management of oxaliplatin-induced peripheral neuropathy. Therapeutics and clinical risk management. 2005 Dec;     [PubMed PMID: 18360567]

[32]

Kurk SA, Peeters PHM, Dorresteijn B, de Jong PA, Jourdan M, Kuijf HJ, Punt CJA, Koopman M, May AM. Impact of different palliative systemic treatments on skeletal muscle mass in metastatic colorectal cancer patients. Journal of cachexia, sarcopenia and muscle. 2018 Oct:9(5):909-919. doi: 10.1002/jcsm.12337. Epub 2018 Aug 24     [PubMed PMID: 30144305]

[33]

Sharief U, Perry DJ. Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin. Clinical colorectal cancer. 2009 Jul:8(3):163-5. doi: 10.3816/CCC.2009.n.026. Epub     [PubMed PMID: 19632931]

[34]

Cersosimo RJ. Oxaliplatin-associated neuropathy: a review. The Annals of pharmacotherapy. 2005 Jan:39(1):128-35     [PubMed PMID: 15590869]

[35]

Takimoto CH,Remick SC,Sharma S,Mani S,Ramanathan RK,Doroshow JH,Hamilton A,Mulkerin D,Graham M,Lockwood GF,Ivy P,Egorin M,Greenslade D,Goetz A,Grem JL, Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the national cancer institute organ dysfunction working group. Seminars in oncology. 2003 Aug;     [PubMed PMID: 14523791]

[36]

Ryu CG, Jung EJ, Kim G, Kim SR, Hwang DY. Oxaliplatin-induced Pulmonary Fibrosis: Two Case Reports. Journal of the Korean Society of Coloproctology. 2011 Oct:27(5):266-9. doi: 10.3393/jksc.2011.27.5.266. Epub 2011 Oct 31     [PubMed PMID: 22102978]

Level 3 (low-level) evidence

[37]

Pissarra A, Malheiro M, Matos LV, Plácido AN. Severe rhabdomyolysis related to oxaliplatin adjuvant therapy for colorectal cancer. BMJ case reports. 2019 Apr 16:12(4):. doi: 10.1136/bcr-2018-228673. Epub 2019 Apr 16     [PubMed PMID: 30996068]

Level 3 (low-level) evidence

[38]

Janinis J, Papakostas P, Samelis G, Skarlos D, Papagianopoulos P, Fountzilas G. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study. Annals of oncology : official journal of the European Society for Medical Oncology. 2000 Feb:11(2):163-7     [PubMed PMID: 10761750]

Level 2 (mid-level) evidence

[39]

Rogers JE, Dasari A, Eng C. The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. The oncologist. 2016 May:21(5):563-70. doi: 10.1634/theoncologist.2015-0362. Epub 2016 Mar 21     [PubMed PMID: 27000464]

[40]

. Oxaliplatin. Drugs and Lactation Database (LactMed®). 2006:():     [PubMed PMID: 33226756]

[41]

Gamelin L, Boisdron-Celle M, Delva R, Guérin-Meyer V, Ifrah N, Morel A, Gamelin E. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Jun 15:10(12 Pt 1):4055-61     [PubMed PMID: 15217938]

Level 2 (mid-level) evidence